• Submitted by: Luis Manuel Mazorra
• Health and Medicine
• 04 / 12 / 2012

---

The efficacy of topical recombinant interferon alpha 2B will be tested in a clinical trial to be held in eastern Cuba. This is intended to medically treat the recurrence of actinic keratosis.
Dr. Orestes Marino, director of Ophthalmic surgical hospital Lucia Iñiguez clinical, of this city, told AIN that the product is a new implementation of the Center for Genetic Engineering and Biotechnology (ICGEB) in Havana.

  Solution that can be added to control tissue regeneration processes premalignant eye previously treated by surgery, which usually lead to squamous cell and basal cancers.

  He explained that both the Eye Center in Holguin, like those in Las Tunas, Granma, Santiago de Cuba and Guantanamo who will participate in the study, they expect the drug to begin, which will be of type A double-blind.

  Marino said that in each participating province are selected to serve on the 20 patients in the sample, a process that involves specialists in Cornea and Oculoplasty, Pathology, Clinical Laboratory and other medical branches.

  Eye Center director Holguin added that this form of keratosis, pterygium-like, is characterized by the proliferation of fibroid tissue and dysplastic, which affects the conjunctiva and cornea, which in the first instance requires immediate surgical treatment.

  Clinical trials, said Dr. Ernesto Hernandez, coordinator, are a necessary step in the development of biotechnology products for the treatment of various diseases.

  This particular study, he said, aims to find an effective treatment to reduce precancerous lesions such as actinic keratosis, in favor of the quality of life of those who suffer, eye disease that has high prevalence, mainly in eastern Cuba.